BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Week In Review | Feb 4, 2013
Company News

SciClone, Sanofi sales and marketing update

SciClone announced that it and Sanofi agreed to group together and renew until Dec. 31 deals in which Sanofi granted SciClone exclusive commercialization rights to four of its products in China. The products are Depakine...
BC Week In Review | Aug 1, 2011
Clinical News

Trobalt retigabine regulatory update

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Mississauga, Ontario   Meda AB (SSE:MEDAA), Solna, Sweden   GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.   Product: Trobalt retigabine ( Potiga ezogabine - U.S.)   Business: Neurology   The U.K.'s NICE...
BC Week In Review | Jun 27, 2011
Clinical News

Depakene sodium valproate regulatory update

Japan's Ministry of Health, Labor, and Welfare (MHLW) approved an expanded label for Depakene sodium valproate from Kyowa Hakko Kirin to suppress the onset of migraine attacks. Depakene is already marketed to treat epilepsy and...
BC Week In Review | Jun 20, 2011
Clinical News

Potiga ezogabine regulatory update

FDA approved an NDA from Valeant for Potiga ezogabine as an adjunctive treatment for partial onset seizures in adults. Valeant and partner GlaxoSmithKline expect to launch the product in the U.S. by year end. The...
BC Extra | Jun 17, 2011
Company News

NICE recommends Trobalt for seizures

The U.K.'s NICE issued draft guidance recommending the use of Trobalt retigabine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) as adjunctive treatment for partial onset seizures for adults who have epilepsy if other treatments have been ineffective...
Items per page:
1 - 6 of 6